Pieris Pharmaceuticals (NSDQ:PIRS) has closed an underwritten public offering of 6,325,000 shares of its common stock. The Boston, Mass.-based company said it reeled in $50.6 million from the offering, which it plans to use to fund the pre-clinical and clinical development of its pipeline. Get the full story at our sister site, Drug Delivery Business News.
Funding Roundup
Mitralign raises $10m
Mitralign, which is looking to commercialize its namesake mitral valve treatment and pursue regulatory nods for its Trialign tricuspid valve device, said it raised nearly $10 million. The $9.8 million funding, of a hoped-for $30.2 million, came from 19 unnamed investors beginning last September, the Tewksbury, Mass.-based company said in a regulatory filing. Mitralign raised […]
Procept BioRobotics raises $118m for Aquablation prostate treatment
Procept BioRobotics said today that it raised $118 million in an equity round it plans to use on the commercialization of its Aquablation treatment for benign prostate hyperplasia. Redwood Shores, Calif.-based Procept said new backer Viking Global Investors led the round, joined by Perceptive Advisors and existing investors including CPMG. The Aquablation treatment combines Procept’s Aquabeam – […]
Siemens plans EU-based IPO for Healthineers division
Siemens (NYSE:SI) subsidiary Healthineers yesterday announced plans for a German initial public offering it expects to complete during the first half of 2018. Parent company Siemens said the IPO will consist of a secondary offering of shares from existing holdings of Siemens and is planned to post on the Regulated Market of the Frankfurt Stock Exchange. Siemens […]
Motus GI closes $18m IPO
Motus GI last week closed an initial public offering worth $18 million for its Pure-Vu system for intra-colonoscopy cleaning. Fort Lauderdale-based Motus said it plans to use the proceeds to commercialize Pure-Vu and for R&D, among other things. The company said it sold 3.5 million shares at $5 apiece, grossing $17.5 million, and also granted a 30-day […]
Motus GI downsizes IPO to $18m
Motus GI today priced its upcoming initial public offering, dropping the range from a midpoint of $26 million to a total of $18 million. In the offering, the Fort Lauderdale, Fla.-based company said it will offer 3.5 million shares of common stock at $5 per share, with its shares slated to begin trading on Nasdaq today […]
Pieris Pharmaceuticals prices $44m public offering
Pieris Pharmaceuticals (NSDQ:PIRS) today priced an underwritten public offering of 5.5 million shares of its common stock at $8.00 per share. The company said it expects to generate $44 million from the offering, which it will use to fund the pre-clinical and clinical development of its pipeline. Get the full story at our sister site, Drug Delivery Business […]
HeartFlow closes $240m Series E
HeartFlow said today it closed a $240 million Series E round of financing, with funds slated to support commercial expansion and studies of its HeartFlow FFRct analysis system. Redwood City, Calif.-based HeartFlow’s FFRct technology works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing the changes […]
Tandem closes $69m underwritten public offering
Tandem Diabetes Care (NSDQ:TNDM) has closed its previously-announced underwritten public offering of 30 million shares of common stock at $2.00 apiece. The San Diego, Calif.-based company reeled in $69 million from the offering, after underwriters exercised an option to buy 4.5 million additional shares of Tandem’s common stock. Get the full story at our sister site, Drug Delivery […]
Viveve closes $32m offering
Viveve (NSDQ:VIVE) said today it closed a $32.4 million offering with funds slated to support continued research and development and commercialization of its products. The Englewood, Colo.-based company said it sold a total of 11.5 million shares of stock at $3 per share, including shares sold during the full exercise of an underwriters option to purchase […]
NovaBay raises $6m in private placement
NovaBay Pharmaceuticals (NYSE:NBY) has raised nearly $6 million after selling 1.7 million shares of common stock to OP Financial Investments Ltd., an institutional investor listed on the Hong Kong stock exchange. The Emeryville, Calif.-based company is developing non-antibiotic products for the topical anti-infective market. Its Avenova product is designed for the removal of microorganisms and debris on […]